![]() ![]() | Generic Hydrea (Hydroxyurea)Cancer Drug | ||||||||||||||||||||
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Most popular quantity. Information About Generic Hydrea (Hydroxyurea)What is Generic Hydrea (Hydroxyurea)Working of Generic Hydrea (Hydroxyurea)Generic Hydrea (Hydroxyurea) Dosage or AdministrationPrecautions for Taking Generic Hydrea (Hydroxyurea)Interaction of Generic Hydrea (Hydroxyurea) with Other DrugsSide effects of Generic Hydrea (Hydroxyurea)
Hydroxyurea is generic equivalent of Hydrea, it is used to Reduce frequency of painful crises and need for blood transfusion in adults with sickle cell anemia with recurrent moderate-to-severe painful crises; treatment of melanoma; resistant chronic myelocytic leukemia (CML); recurrent, metastatic, or inoperable carcinoma of ovary; as an adjunct to irradiation in local control of primary squamous cell carcinomas of head and neck, excluding lip. What is Generic Hydrea (Hydroxyurea)Generic Hydrea belong to calss Antisickling / Antimetabolite. Generic Hydrea Inhibits DNA synthesis, interferes with conversion of ribonucleotides to deoxyribonucleotides, and may inhibit incorporation of thymidine into DNA. Hydroxyurea is readily absorbed from the GI tract, reaching peak serum concentrations within » 1 to 2 hr. About 50% of an oral dose is degraded in the liver and excreted into the urine as urea and as respiratory carbon dioxide; the remainder is excreted intact in the urine. Generic Hydrea (Hydroxyurea) Dosage or AdministrationSickle Cell Anemia ADULTS: PO Initial dose 15 mg/kg/day as a single dose. If blood counts are acceptable levels, dose may be increased by 5 mg/kg/day q 12 wk until max tolerated dose (ie, highest dose not producing toxic blood counts over 24 consecutive wk), or 35 mg/kg/day is reached. Dose is not increased if blood counts are between acceptable and toxic levels.
If blood counts are considered toxic, discontinue hydroxyurea until hematologic
recovery, then resume therapy after reducing dose by 2.5 mg/kg/day from dose
associated with hematologic toxicity. Then, titrate dose up or down q 12 wk
in 2.5 mg/kg/day increments until patient is at a stable dose that does not
result in hematologic toxicity for 24 wk. Any dose that produces hematologic
toxicity twice should not be given again. Precautions for Taking Generic Hydrea (Hydroxyurea)Pregnancy: Category D. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Elderly: May be more sensitive to the effects of hydroxyurea and may require a lower dosage regimen. Bone marrow function: Because hydroxyurea is cytotoxic and myelosuppressive, do not administer if bone marrow function is markedly depressed. Erythema: Patients who have received prior irradiation therapy may have an exacerbation of postirradiation erythema. Erythrocytic abnormalities: Self-limiting megaloblastic erythropoiesis is often seen early in hydroxyurea therapy. Renal toxicity: May temporarily impair renal tubular function accompanied by elevated serum uric acid, BUN, and creatinine levels. Carcinogenesis: Hydroxyurea is presumed to be a human carcinogen. Interaction of Generic Hydrea (Hydroxyurea) with Other DrugsFluoruracil Coadministration may cause neurotoxicity. Side effects of Generic Hydrea (Hydroxyurea)DERMATOLOGIC: Hair loss; skin rash; black-pigmented nails; maculopapular rash,
skin ulcers, dermatomyositis-like changes, peripheral and facial erythema; hyperpigmentation;
skin and nail atrophy; scaling and violet papules; skin cancer. GI: Stomatitis;
anorexia; nausea; vomiting; diarrhea; constipation; increased LFTs. HEMATOLOGIC:
Neutropenia; low reticulocyte and platelet levels; bleeding; bone marrow suppression.
METABOLIC: Weight gain. RESPIRATORY: Pulmonary infiltrates and fibrosis. RENAL:
Temporary impairment of renal tubular function; uric acid nephropathy. OTHER:
Fever; parvovirus B-19 infection; chills; malaise. | |||||||||||||||||||||